BioMarin Pharmaceutical Inc. - Common Stock (NQ:BMRN)

55.74 -0.01 (-0.02%)

Delayed Quote Updated: 2:19 PM EDT, Oct 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BioMarin Pharmaceutical Inc. - Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

19 20 Next >

Palo Alto Networks To Rally More Than 16%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

August 20, 2024

Via Benzinga

NASDAQ:BMRN is not too expensive for the growth it is showing. ↗

August 14, 2024

While growth is established for BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN), the stock's valuation remains reasonable.

Via Chartmill

$1000 Invested In Biomarin Pharmaceutical 20 Years Ago Would Be Worth This Much Today ↗

August 07, 2024

Via Benzinga

Rare Disease-Focused BioMarin Narrows Sales Focus, Cuts Cost For Hemophilia A Gene Therapy; Lifts Annual Guidance ↗

August 06, 2024

BioMarin Pharmaceutical shifts focus to commercial operations for Roctavian in the U.S., Germany, and Italy. Projected cost reductions aim to achieve profitability by 2025. Strong Q2 performance driven...

Via Benzinga

Yum China Posts Upbeat Earnings, Joins Clear Secure, TG Therapeutics, Bioventus And Other Big Stocks Moving Higher On Tuesday ↗

August 06, 2024

Via Benzinga

Investors seeking growth at a reasonable cost should explore NASDAQ:BMRN. ↗

July 24, 2024

BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN), a growth stock which is not overvalued.

Via Chartmill

$1000 Invested In This Stock 20 Years Ago Would Be Worth $16,000 Today ↗

July 16, 2024

Via Benzinga

Biomarin Pharmaceutical Analysts Boost Their Forecasts Following Better-Than-Expected Q2 Results ↗

August 06, 2024

Via Benzinga

BMRN Stock Earnings: Biomarin Pharmaceutical Beats EPS, Beats Revenue for Q2 2024 ↗

August 05, 2024

BMRN stock results show that Biomarin Pharmaceutical beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Via InvestorPlace

A Glimpse Into The Expert Outlook On Biomarin Pharmaceutical Through 10 Analysts ↗

July 22, 2024

Via Benzinga

$100 Invested In Biomarin Pharmaceutical 20 Years Ago Would Be Worth This Much Today ↗

July 18, 2024

Via Benzinga

Peering Into Biomarin Pharmaceutical's Recent Short Interest ↗

July 04, 2024

Via Benzinga

Investors should take note of NASDAQ:BMRN, a growth stock that remains attractively priced. ↗

July 02, 2024

Investors should take note ofBIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN), a growth stock that remains attractively priced.

Via Chartmill

Cracking The Code: Understanding Analyst Reviews For Biomarin Pharmaceutical ↗

June 27, 2024

Via Benzinga

Looking Into Biomarin Pharmaceutical's Recent Short Interest ↗

May 28, 2024

Via Benzinga

NASDAQ:BMRN is not too expensive for the growth it is showing. ↗

May 21, 2024

Looking for growth without the hefty price tag? Consider BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN).

Via Chartmill

For those who appreciate growth without the sticker shock, NASDAQ:BMRN is worth considering. ↗

June 11, 2024

While growth is established for BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN), the stock's valuation remains reasonable.

Via Chartmill

CrowdStrike, KKR, GoDaddy To Join S&P 500 In Quarterly Rebalance; Stocks Jump ↗

June 07, 2024

KKR and GoDaddy also will join before the open on June 24.

Via Investor's Business Daily

Topics Stocks

June’s Biotech Boom: 3 Stocks to Buy for a Summertime Surge ↗

June 05, 2024

Biotech surge alert! Discover three biotech stocks to buy as they catch up with the market in the rest of 2024.

Via InvestorPlace

10 Health Care Stocks Whale Activity In Today's Session ↗

June 04, 2024

Via Benzinga

Analyst Ratings For Biomarin Pharmaceutical ↗

May 14, 2024

Via Benzinga

(BMRN) - Analyzing Biomarin Pharmaceutical's Short Interest ↗

May 09, 2024

Via Benzinga

BridgeBio Stock Makes A Bullish Move On Dwarfism Treatment Results ↗

June 04, 2024

BridgeBio stock rallies on upbeat study results of a drug for a genetic disease that affects the limbs and spine.

Via Investor's Business Daily

Li Auto Was One Of The Worst-Performing Stocks Last Week: Are These 10 Large-Cap Stocks Losers In Your Portfolio? (May 12-May 18, 2024) ↗

May 19, 2024

Last week, these 10 large-cap stocks had the worst performance. NICE, PBR, FIX, LI, MLM, VMC, BMRN, EDU, GFI, MUFG all saw significant decreases.

Via Benzinga

4 Incomparable Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market ↗

May 18, 2024

Plain-as-day bargains can still be found, even with the innovation-fueled Nasdaq Composite powering to a fresh all-time high.

Via The Motley Fool

Topics Stocks

Walmart To Rally Over 17%? Here Are 10 Top Analyst Forecasts For Friday ↗

May 17, 2024

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

May 15, 2024

Via Benzinga

The 3 Best Biotech Stocks to Buy in May 2024 ↗

May 09, 2024

If you have the appetite for the risk inherent in the biotech sector, here are three biotech stocks to buy in May.

Via InvestorPlace

Citi Just Cut Its Price Target on These 3 Stocks ↗

May 03, 2024

Reviewing analyst downgrades may help safeguard investment portfolios amid market uncertainty and Citi price target cuts.

Via InvestorPlace

For those who appreciate growth without the sticker shock, NASDAQ:BMRN is worth considering. ↗

April 30, 2024

For those who appreciate growth without the sticker shock, NASDAQ:BMRN is worth considering.

Via Chartmill

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

19 20 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.